featured
Surufatinib in Advanced Pancreatic Neuroendocrine Tumors
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Surufatinib in Advanced Pancreatic Neuroendocrine Tumours (SANET-p): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Study
Lancet Oncol 2020 Sep 18;[EPub Ahead of Print], J Xu, L Shen, C Bai, W Wang, J Li, X Yu, Z Li, E Li, X Yuan, Y Chi, Y Yin, W Lou, N Xu, Y Bai, T Zhang, D Xiu, X Wang, Y Yuan, J Chen, S Qin, R Jia, M Lu, Y Cheng, Z Zhou, J Li, J He, W SuFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.